#Switzerland #Basel #Jungbunzlauer #Tricalcium Citrate #Direct Compression

Jungbunzlauer's Tricalcium Citrate Excipients

Jungbunzlauer, a global leader in high-quality sustainable ingredients, recently announced outstanding results for their Tricalcium Citrate excipients (TCC TB) following a collaborative research study with Professor Karl Wagner from the University of Bonn. This innovative effort has set a new benchmark for the direct compression of tablets in both pharmaceutical and nutraceutical industries.

Direct compression is increasingly favored for its efficiency and suitability for sensitive ingredients. However, it necessitates excipients that possess excellent flowability and compactibility. The newly published study compellingly shows that TCC TB offers exceptional flow characteristics, resulting in robust tablets despite low compression forces and quick disintegration rates. This is particularly significant for complex formulations including mini-tablets, moisture-sensitive active ingredients, and botanical actives.

The TCC TB product is achieved by completely neutralizing citric acid with a high-purity calcium source. It's not only vegan and free from allergens and GMOs but also complies with prominent standards, including USP, FCC, and EU norms.

Markus Gerhart, the senior category manager for Minerals and Solutions at Jungbunzlauer, emphasized their commitment to rigorous science, innovation, and product excellence. “We take pride in demonstrating that our TCC TB delivers reliable performance in direct compression, thereby enabling our clients to achieve efficiency, quality, and trust,” he stated.

The new findings will be showcased at CPHI Global, taking place from October 28 to 30, 2025, at Messe Frankfurt (Hall 8, Stand Q55). Attendees will have the opportunity to discuss the data with Jungbunzlauer representatives, exploring how TCC TB can naturally support their next formulation challenges.

About Jungbunzlauer

Founded over 150 years ago, Jungbunzlauer operates from Basel, Switzerland, and is dedicated to producing sustainable, high-quality ingredients from natural sources. Their offerings cater to a wide array of industries such as food, beverages, nutrition, health, home care, and personal care. With modern facilities including large-scale fermentation plants in Europe and North America, the company serves over 130 countries worldwide, boasting a revenue of 1.3 billion Swiss francs and employing nearly 1,400 professionals committed to a healthier and sustainable future. For more information, visit Jungbunzlauer's website.

In conclusion, the advancements with Tricalcium Citrate excipients not only affirm Jungbunzlauer's leadership in the sustainable ingredients sector but also highlight the significance of rigorous research in advancing manufacturing processes for pharmaceuticals and nutraceuticals. As the industry evolves, innovations such as TCC TB will undoubtedly play a critical role in shaping the future of direct compression techniques.